Real-life effect of long-acting β2-agonist withdrawal in patients with controlled step 3 asthma

Sunny Jabbal, Arvind Manoharan, William Anderson, Joseph Lipworth (Lead / Corresponding author), Brian Lipworth (Lead / Corresponding author)

Research output: Contribution to journalLetter

2 Citations (Scopus)


Approximately 45% of patients with asthma in the United Kingdom are receiving step 3 or higher therapy,1 most commonly inhaled corticosteroids (ICSs) and long-acting β2-agonists (LABAs). The 2016 Global Initiative for Asthma (GINA) guidelines propose a cycle of assessment, stepwise adjustment of treatment, and review of response to ascertain the lowest treatment to achieve control.2 In addition, the US Food and Drug Administration advocates stopping use of LABAs once asthma control is achieved and maintained and switching to ICS monotherapy.
Original languageEnglish
Pages (from-to)430-431
Number of pages2
JournalAnnals of Allergy, Asthma & Immunology
Issue number4
Early online date9 Aug 2016
Publication statusPublished - Oct 2016


Cite this